Introduction
============

Along with widespread use of prostate-specific antigen (PSA) for screening and early detection of prostate cancer (PCa),[@b1-ott-11-3883]--[@b3-ott-11-3883] the diagnosis of PCa has abruptly shifted with concurrent improvement of transrectal ultrasound (TRUS)-guided prostate biopsy.[@b4-ott-11-3883],[@b5-ott-11-3883] However, PSA is an imperfect serum marker; the American Cancer Society reports a sensitivity of only 21% for any PCa, while specificity is 91% when the normal PSA level is defined as less than 4.0 ng/mL.[@b6-ott-11-3883] Therefore, approximately 80% of patients will receive an unnecessary biopsy, and some patients will suffer over-diagnosis and the associated over-treatment.[@b7-ott-11-3883]--[@b9-ott-11-3883] In addition, TRUS-guided prostate biopsy is an invasive procedure that can cause hematuria, hematochezia, urinary tract infection, and bacteremia.[@b10-ott-11-3883]--[@b12-ott-11-3883] Consequently, a more reliable biomarker is needed to supplement PSA for the diagnosis of PCa.

To date, natural killer (NK) cells have gained increasing attention in the cancer setting, as they are involved in innate immunity and serve a major role in anticancer mechanisms.[@b13-ott-11-3883],[@b14-ott-11-3883] NK cells show potent natural cytotoxicity to eliminate cancer cells directly and also play a role in the adaptive immune system by secreting cytokines that suppress tumor progression.[@b15-ott-11-3883]--[@b17-ott-11-3883] The relationship between natural killer cell activity (NKA) and cancer has been studied for many decades, and reduction of NKA is associated with advanced stage PCa, progression of PCa, and the presence of circulating tumor cells.[@b18-ott-11-3883]--[@b20-ott-11-3883] However, application of NKA as a marker for the detection and risk assessment of PCa has not been fully investigated.

To address these issues, we measured NKA in patients who were diagnosed with PCa or who underwent TRUS-guided prostate biopsy for suspected PCa. The aim of this study is to analyze the clinical usefulness of NKA for the diagnosis of PCa in patients with suspected PCa, and to examine whether NKA correlated with the Gleason grade of PCa.

Patients and methods
====================

Patients and data collection
----------------------------

This observational cross-sectional study was approved by the Institutional Review Board of Samsung Medical Center, and written informed consent was obtained from each study participant. We enrolled 223 patients who underwent TRUS-guided prostate biopsy for suspected PCa due to elevated PSA \>2.5 ng/mL and/or abnormal findings on digital rectal examination (n=147), or who were diagnosed with PCa (n=76) between November 2016 and July 2017.

Eligible criteria for enrollment were as follows: 1) male aged 40 to 75 years, 2) no history of diagnosis or treatment for other malignancies, 3) no history of neoadjuvant androgen deprivation therapy for PCa, and 4) no history of inflammatory conditions that might affect the immune system. From these patients, we excluded two who had incomplete data for Gleason grade. Ultimately, 221 patients were analyzed in our study.

Data collection
---------------

The clinical characteristics of the patients including age, PSA, and NKA were recorded. For patients diagnosed with PCa, Gleason grade was recorded using the new grading system proposed in the 2014 consensus of International Society of Urological Pathology.[@b21-ott-11-3883] We divided the patients into two groups according to the presence of PCa, and NKA was compared between the two groups and according to Gleason grade. The absolute risk and relative risk of PCa and odds ratios at different cut-off values of NKA were calculated.

Measurement of NKA
------------------

Cytotoxic activity of NK cells was measured using the NK Vue^®^ Kit (ATgen, Sungnam, Korea). One milliliter of whole blood was collected using NK Vue Tubes and placed into the incubator at 37°C for 24 hours under 5% CO~2~ with the indicated dose of Promoca™ (ATGen, Seongnam-si, Korea) and 1 mL of RPMI 1640 medium (Cellgro/Mediatech, Manassas, VA, USA). After that, the supernatant was collected and centrifuged at 11,500× *g* for 5 minutes. The supernatant was collected in another conical 1.5 mL Eppendorf tube and immediately loaded onto the enzyme-linked immunosorbent assay (ELISA) plates.

During the 24 hours' incubation at 37°C, stimulatory cytokine (Promoca) stimulated the NKA and IFN-g secreted into the plasma was quantitated with an ELISA. IFN-g was measured in pg/mL and the dynamic range of the ELISA was from 40 to 2,000 pg/mL. When the measured level of IFN-g was below or above the dynamic range, it was recorded as a value of 40 pg/mL or 2,000 pg/mL, respectively.

Statistical analysis
--------------------

Quantitative variables were expressed as median (range) or mean (SD) and qualitative variables as absolute values (percentage). An independent *t*-test was used to compare age, PSA, and NKA. Correlation analysis was used to evaluate associations among NKA, PCa, and Gleason grade, and expressed using distribution dot plots. NKA according to Gleason grade was compared using one-way analysis of variance. All statistical analyses were performed using IBM SPSS statistics for Window, version 23.0 (IBM Corporation, Armonk, NY, USA) and MedCalc version 13.0 (MedCalc Software, Mariakerke, Belgium). Two-tailed *P*-values \<0.05 were considered statistically significant.

Results
=======

The baseline characteristics of all 221 patients with suspected or diagnosed PCa are summarized in [Table 1](#t1-ott-11-3883){ref-type="table"}. Among the total 221 patients, the median age was 66.0 years. Median PSA and NKA were 5.78 ng/mL and 1,337.8 pg/mL, respectively. Gleason grade confirmed by TRUS-guided biopsy was as follows: Gleason grade 6 for 43 (31.9%) patients, Gleason grade 7 (3+4) for 34 (25.1%) patients, Gleason grade 7 (4+3) for 15 (11.1%) patients, Gleason grade 8 for 25 (18.6%) patients, and Gleason grade 9--10 for 18 (13.3%) patients. When patients were divided into two groups according to the presence of PCa, a significant difference was identified in age (*P*=0.001) but not in PSA (*P*=0.066) or NKA (*P*=0.491, [Figure 1](#f1-ott-11-3883){ref-type="fig"}). In addition, when we restricted the analysis to patients with PSA between 2.5 and 10.0 ng/mL, patients with PCa were older (*P*=0.019) and had higher PSA (*P*=0.031) than patients without. However, NKA was not significantly different (*P*=0.654).

NKA according to Gleason grade is presented in [Table 2](#t2-ott-11-3883){ref-type="table"}. Median NKA was as follows: 1,394.9 pg/mL for Gleason grade 6, 1,519.5 pg/mL for Gleason grade 7 (3+4), 2,000.0 pg/mL for Gleason grade 7 (4+3), 1,329.1 pg/mL for Gleason grade 8, and 1,505.7 pg/mL for Gleason grade 9--10. There was no significant difference in NKA values among Gleason grade groups (*P*=0.893, [Figure 2](#f2-ott-11-3883){ref-type="fig"}). The results in patients with PSA between 2.5 and 10.0 ng/mL were also not significantly different based on Gleason grade (*P*=0.672).

The risk of PCa at different cut-off values of NKA is detailed in [Table 3](#t3-ott-11-3883){ref-type="table"}. Among all 221 patients, when the NKA value was less than 200 pg/mL, the absolute risk of PCa was 63.2% (12/19). The absolute risk of PCa in patients with an NKA value more than 200 pg/mL was 60.9% (123/202). The corresponding relative risk (95% CI) and odds ratio (95% CI) were 1.04 (0.72--1.49) and 1.10 (0.42--2.91), respectively, demonstrating that there was no significant difference in the risk of PCa based on an NKA cut-off of 200 pg/mL. The risk of PCa in patients with PSA between 2.5 and 10.0 ng/mL at different cut-off values of NKA is summarized in [Table 3](#t3-ott-11-3883){ref-type="table"}.

Discussion
==========

Among the 221 total patients enrolled in the present study, PCa was identified in 135 (61.9%). When patients were divided into two groups according to the presence of PCa, there was no significant difference in the value of NKA (*P*=0.491). In addition, for the 135 patients with PCa, the value of NKA was not significantly different according to Gleason grade (*P*=0.893). These results did not change when restricted to patients with PSA between 2.5 and 10.0 ng/mL (*P*=0.654 and *P*=0.672, respectively). Our results suggest that the value of NKA is not very useful for detection of PCa and prediction of Gleason grade. To the best of our knowledge, this is the first and largest study to evaluate correlations among NKA, PCa detection, and Gleason grade.

Recently, immunotherapy has been developed that can counteract cancer-mediated immunosuppression for solid tumors, such as PCa, with a focus on alternative therapeutic options for metastatic cancer. In particular, NK cells play an important role in tumor immuno-surveillance because they activate both the innate and adaptive immune responses in reaction to tumor cells, even without surface antigens.[@b22-ott-11-3883],[@b23-ott-11-3883] NK cells exert their natural cytotoxicity to remove malignant cells without presensitization.[@b15-ott-11-3883] In addition, they prompt the adaptive immune response to cope with the escape mechanism of tumor cells by secreting pro-inflammatory cytokines.[@b16-ott-11-3883] NKA is regulated by various activating and inhibitory receptors on the cell surface, thereby initiating cytolytic processes in tumor cells and avoiding tissue damage.[@b13-ott-11-3883] Consequently, the role of NK cells in metastatic PCa has previously been explored in several studies.[@b24-ott-11-3883],[@b25-ott-11-3883]

Lin et al[@b25-ott-11-3883] evaluated the role of NK cells in vitro in castration-resistant PCa (CRPC) cell lines (CWR22Rv1 and VCaP, both enzalutamide-resistant) and found that CRPC cells collected NK cells more readily than normal prostate cells. These recruited NK cells decreased enzalutamide-resistant CRPC cell growth and invasion by suppressing ARv7 expression. In response, however, CRPC cells avoided the anticancer activity of NK cells through an immunosuppressive reaction of secreting an NKG2D ligand-expressing PCa-derived exosome.[@b26-ott-11-3883]

Furthermore, Pasero et al[@b24-ott-11-3883] isolated NK cells from the peripheral blood of 39 patients with metastatic PCa and evaluated their relationship with overall survival (OS, time from diagnosis of metastases to death or last follow-up) and time to castration resistance (TCR, time from castration to castration resistance). They found that high activity of NK cells was significantly associated with longer OS, and longer TCR, of more than 18 months. In addition, NKp30 and NKp46, which are activating receptors involved in the recognition of PCa by NK cells, are significant predictive markers for longer OS and TCR. Collectively, higher NKA provided favorable clinical outcomes that could be used as a potential new therapy in CRPC patients.

However, in contrast to previous studies, we observed that NKA measured in the peripheral blood was not significantly associated with detection of PCa and Gleason grade. There are several possible explanations for this discrepancy. First, among the 135 patients with PCa, the PSA was less than 20 ng/mL in 114 (84.4%) patients, and biopsy Gleason grade 7 or less was identified in 92 (68.1%) patients, indicating that most patients with PCa are not high-risk. In addition, when confined to patients with PSA between 2.5 and 10.0 ng/mL, 80.9% (72/89) of patients had Gleason grade 7 or less. Early pilot studies demonstrated that NKA was significantly lower in patients with advanced PCa, but not different in localized PCa.[@b19-ott-11-3883],[@b27-ott-11-3883] In addition, Pasero et al[@b28-ott-11-3883] found that prostatic tissues are not properly infiltrated by NK cells and described a low frequency of NK cells in both normal prostate tissue and PCa tissue.

Second, NK cells are generally categorized into CD16^+^ CD56^dim^ and CD16^−^ CD56^bright^ subsets according to membrane densities of CD16 and CD56.[@b29-ott-11-3883] CD56^dim^ cells make up 90%--95% of NK cells and exert high cytotoxic potential, while CD56^bright^ cells are considered immature but acquire greater cytolytic activity than CD56^dim^ cells when activated by pro-inflammatory cytokines. When examining the pattern of distribution of NK cells, CD56^dim^ cells are often dominant in the peripheral blood, while CD56^bright^ cells are significantly enriched in tissues regardless of PCa invasion. Consequently, the NKA of patients with stable PCa was not significantly different from that of patients with a normal prostate.

A recent pilot study evaluated the association between NKA and PCa in 43 patients eligible for TRUS-guided prostate biopsy, measuring NKA with an in vitro diagnostic device (IVDD) using 1 mL of whole blood.[@b30-ott-11-3883] Of the total 43 patients, 21 (48.8%) were diagnosed with PCa and, at a cut-off value of NKA less than 200 pg/mL, IVDD-measured NKA provided a sensitivity of 57%, specificity of 91%, positive predictive value of 86%, and negative predictive value of 69%. Therefore, the absolute risk of having PCa with this cut-off value of IVDD-measured NKA was 86%. However, these results conflict with our findings that NKA was not significantly associated with PCa detection. As the pilot study was conducted in a small number of patients with patient characteristics and PSA that were different from our study, further study in a larger population is needed to verify the implications of our results.

This study has several limitations to consider when interpreting our results. First, the measurement of NKA in the peripheral blood was only performed prior to TRUS-guided prostate biopsy and was not checked again in patients with PCa after definite treatment; thus, serial changes of NKA were not evaluated. Second, as our study focused on the clinical application of NKA for the detection of PCa and the prediction of Gleason grade, we did not verify our results at the cellular level in normal or cancerous prostate tissue. Third, as fluorescence-activating cell sorting analysis or K562 cytotoxicity assay could measure NKA more accurately, additional study for verification is warranted.

In conclusion, precise detection of PCa and prediction of Gleason grade are important to establish a treatment plan, and an additional diagnostic test is required to better determine the risk of PCa. Although NK cells play a significant role in tumor cell immunosurveillance, NKA does not appear to be very useful for detection of PCa or prediction of Gleason grade. Further large, multi-institutional studies are required to verify the role of NKA in PCa detection and Gleason grade prediction.
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###### 

Baseline characteristics

  Parameters                                     Prostate cancer           *P*-value                                           
  ---------------------------------------------- ------------------------- ------------------------- ------------------------- -------
  Overall patients                                                                                                             
   N                                             221 (100.0)               135 (61.9)                86 (38.9)                 
  Age, years                                                                                                                   0.001
   Median (range)                                66.0 (39.0--81.0)         67.0 (50.0--81.0)         64.0 (39.0--80.8)         
   Mean (SD)                                     65.5 (7.6)                66.9 (7.1)                63.3 (7.9)                
  PSA, ng/mL                                                                                                                   0.066
   Median (range)                                5.78 (0.79--1,727.10)     6.61 (0.79--1,727.10)     4.77 (0.80--37.34)        
   Mean (SD)                                     22.04 (128.96)            32.25 (164.37)            6.02 (4.77)               
  NKA, pg/mL                                                                                                                   0.491
   Median (range)                                1,337.8 (40.0--2,000.0)   1,373.0 (40.0--2,000.0)   1,139.1 (40.0--2,000.0)   
   Mean (SD)                                     1,240.9 (721.7)           1,267.6 (742.8)           1,198.9 (687.6)           
  Biopsy Gleason grade                                                                                                         
   6                                                                       43 (31.9)                                           
   7 (3+4)                                                                 34 (25.1)                                           
   7 (4+3)                                                                 15 (11.1)                                           
   8                                                                       25 (18.6)                                           
   9--10                                                                   18 (13.3)                                           
  Patients with PSA between 2.5 and 10.0 ng/mL                                                                                 
   N                                             159 (100.0)               89 (56.0)                 70 (44.0)                 
  Age, years                                                                                                                   0.019
   Median (range)                                65.0 (47.0--80.8)         66.0 (50.0--79.0)         64.0 (47.0--80.8)         
   Mean (SD)                                     64.9 (7.2)                66.1 (6.9)                63.4 (7.4)                
  PSA, ng/mL                                                                                                                   0.031
   Median (range)                                5.09 (2.53--9.93)         5.53 (2.53--9.93)         4.67 (2.61--9.06)         
   Mean (SD)                                     5.38 (1.72)               5.64 (1.71)               5.05 (1.70)               
  NKA, pg/mL                                                                                                                   0.654
   Median (range)                                1,342.1 (40.0--2,000.0)   1,375.1 (40.0--2,000.0)   1,143.9 (40.0--2,000.0)   
   Mean (SD)                                     1,241.8 (736.8)           1,265.1 (762.7)           1,212.2 (706.8)           
  Biopsy Gleason grade                                                                                                         
   6                                                                       38 (42.7)                                           
   7 (3+4)                                                                 34 (38.2)                                           
   7 (4+3)                                                                 0                                                   
   8                                                                       10 (11.2)                                           
   9--10                                                                   7 (7.9)                                             

**Abbreviations:** NKA, natural killer cell activity; PSA, prostate-specific antigen.

###### 

NKA according to Gleason grade

  NKA                                            Gleason grade             *P*-value                                                                                                
  ---------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------------------- -------
  Overall patients                                                                                                                                                                  0.893
   Median (range)                                1,394.9 (56.3--2,000.0)   1,519.5 (72.7--2,000.0)   2,000.0 (57.4--2,000.0)   1,329.1 (40.0--2,000.0)   1,505.7 (146.3--2,000.0)   
   Mean (SD)                                     1,349.6 (697.2)           1,246.3 (786.8)           1,311.3 (860.2)           1,173.3 (720.9)           1,206.5 (752.7)            
  Patients with PSA between 2.5 and 10.0 ng/mL                                                                                                                                      0.672
   Median (range)                                1,747.2 (56.3--2,000.0)   1,375.1 (75.6--2,000.0)   720.7 (57.4--2,000.0)     1,277.5 (40.0--2,000.0)   1,724.6 (311.3--2,000.0)   
   Mean (SD)                                     1,375.8 (713.9)           1,246.5 (783.4)           977.1 (924.2)             1,082.0 (809.2)           1,285.9 (812.6)            

**Abbreviations:** NKA, natural killer cell activity; PSA, prostate-specific antigen.

###### 

Risk of prostate cancer according to NKA

  NKA (pg/mL)                                    Total, N (%)   Prostate cancer, N (%)   Absolute risk (%)   Relative risk (95% CI)   Odds ratio (95% CI)   
  ---------------------------------------------- -------------- ------------------------ ------------------- ------------------------ --------------------- -------------------
  Overall patients                                                                                                                                          
   \<200                                         19 (8.6)       12 (63.2)                7 (36.8)            63.2                     1.04 (0.72--1.49)     1.10 (0.42--2.91)
   \<300                                         31 (14.0)      21 (67.7)                10 (32.3)           67.7                     1.13 (0.86--1.48)     1.40 (0.62--3.13)
   \<500                                         51 (23.1)      34 (66.7)                17 (33.3)           66.7                     1.12 (0.89--1.41)     1.37 (0.71--2.64)
   \<800                                         79 (35.7)      49 (62.0)                30 (38.0)           62.0                     1.02 (0.82--1.27)     1.06 (0.60--1.87)
   \<1,000                                       91 (41.2)      52 (57.1)                39 (42.9)           57.1                     0.90 (0.72--1.12)     0.76 (0.44--1.31)
   \<1,300                                       106 (48.0)     60 (56.6)                46 (43.4)           56.6                     0.87 (0.70--1.07)     0.70 (0.40--1.20)
   \<1,500                                       123 (55.7)     71 (57.7)                52 (42.3)           57.7                     0.88 (0.72--1.09)     0.73 (0.42--1.26)
   Total                                         221 (100.0)    135 (61.9)               86 (38.9)           61.9                                           
  Patients with PSA between 2.5 and 10.0 ng/mL                                                                                                              
   \<200                                         15 (9.4)       9 (60.0)                 6 (40.0)            60.0                     1.08 (0.70--1.67)     1.20 (0.41--3.54)
   \<300                                         26 (16.4)      17 (65.4)                9 (34.6)            65.4                     1.21 (0.88--1.66)     1.60 (0.67--3.84)
   \<500                                         39 (24.5)      24 (61.5)                15 (38.5)           61.5                     1.14 (0.84--1.53)     1.35 (0.65--2.83)
   \<800                                         58 (36.5)      32 (55.2)                26 (44.8)           55.2                     0.98 (0.73--1.30)     0.95 (0.50--1.82)
   \<1,000                                       66 (41.5)      34 (51.5)                32 (48.5)           51.5                     0.87 (0.65--1.16)     0.73 (0.38--1.39)
   \<1,300                                       76 (47.8)      40 (52.6)                36 (47.4)           52.6                     0.89 (0.67--1.18)     0.77 (0.41--1.44)
   \<1,500                                       86 (54.1)      46 (53.5)                40 (46.5)           53.5                     0.91 (0.69--1.20)     0.80 (0.43--1.51)
   Total                                         159 (100.0)    89 (56.0)                70 (44.0)           56.0                                           

**Abbreviations:** NKA, natural killer cell activity; PSA, prostate-specific antigen.
